Abatacept

Created

2020-03-04

Last Modified

Files

1 Download↓
rx_2020_03_Abatacept_V1.csv (7.24 KB)
↓

Tags








Abstract

This concept set was intended to identify Abatacept exposures among pediatric nephrology cohorts such as Glomerular Disease or Membranoproliferative Glomerulonephritis (MPGN).

Affiliation(s)

Children's Hospital of Philadelphia

Funder(s)

Provenance

This concept set was developed for the Membranoproliferative Glomerulonephritis (MPGN) in PEDSnet study.

Description

This concept set contains codes pertaining to the medication abatacept. It was developed by authors of Denburg et. al., 2019 (DOI: 10.1681/ASN.2019040365), including Michelle Denburg (clinician), Hanieh Razzaghi (data scientist/informaticist) and Charles Bailey (clinician/informaticist).

Please note: As this concept set was developed five years ago, it should be reviewed and updated prior to reuse in any further studies. Furthermore it is not at the Semantic Clinical Drug Form/Semantic Clinical Drug Group level so does not adhere to current best practices within PEDSnet.

Development Code

https://atlassian.chop.edu/bitbucket/projects/COD/repos/glean_codesets/browse/drug/abatacept.csv

Vocabulary

RxNorm , RxNorm Extension

Clinical Subjects Headings

Abatacept
Selective T Cell Costimulation Modulator
Immunologic Agent

Data Source

Related Phenotype

Related Person

Related Study

Thumbnail Image
Membranoproliferative Glomerulonephritis (MPGN) in PEDSnet
Children's Hospital of Philadelphia
Study to identify and conduct phenotypic characterization of children with C3G and IC-MPGN in PEDSnet using data science and chart review methods. The long-term goal of this work is to perform a large multi-institutional natural history study, compare clinical outcomes in C3G and IC-MPGN, and identify predictors of disease response or progression.

Related Concept Set

Related Publications

Denburg MR, Razzaghi H, Bailey C, Soranno DE, et al. December 2019. “Using Electronic Health Record Data to Rapidly Identify Children with Glomerular Disease for Clinical Research.” JASN 30(12):p 2427-2435. DOI: 10.1681/ASN.2019040365

Creative Commons license

a CC-BY Attribution 4.0 License.
Except where otherwised noted, this item's license is described as a CC-BY Attribution 4.0 License.